Lazertinib Mesylate Patent Expiration
Lazertinib Mesylate was first introduced by Janssen Biotech Inc
Lazertinib Mesylate Patents
Given below is the list of patents protecting Lazertinib Mesylate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Lazcluze | US11850248 | Therapies with 3rd generation EGFR tyrosine kinase inhibitors | Aug 01, 2041 | Janssen Biotech |
| Lazcluze | US11879013 | Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors | May 21, 2040 | Janssen Biotech |
| Lazcluze | US11453656 | Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same | Apr 18, 2038 | Janssen Biotech |
| Lazcluze | US11981659 | Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same | Apr 18, 2038 | Janssen Biotech |
| Lazcluze | US9593098 | Compounds and compositions for modulating EGFR mutant kinase activities | Oct 13, 2035 | Janssen Biotech |
Lazertinib Mesylate's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List